RT Journal Article SR Electronic T1 Biological mechanisms and clinical efficacy of sulforaphane for mental disorders JF General Psychiatry JO Gen Psych FD BMJ Publishing Group Ltd SP e100700 DO 10.1136/gpsych-2021-100700 VO 35 IS 2 A1 Wensi Zheng A1 Xiaolong Li A1 Tianhong Zhang A1 Jijun Wang YR 2022 UL http://gpsych.bmj.com/content/35/2/e100700.abstract AB Current clinical management of major mental disorders, such as autism spectrum disorder, depression and schizophrenia, is less than optimal. Recent scientific advances have indicated that deficits in oxidative and inflammation systems are extensively involved in the pathogenesis of these disorders. These findings have led to expanded considerations for treatment. Sulforaphane (SFN) is a dietary phytochemical extracted from cruciferous vegetables. It is an effective activator of the transcription factor nuclear erythroid-2 like factor-2, which can upregulate multiple antioxidants and protect neurons against various oxidative damages. On the other hand, it can also significantly reduce inflammatory response to pathological states and decrease the damage caused by the immune response via the nuclear factor-κB pathway and other pathways. In this review, we introduce the biological mechanisms of SFN and the pilot evidence from its clinical trials of major mental disorders, hoping to promote an increase in psychiatric clinical studies of SFN.